Expression of double-stranded RNA-activated Protein kinase (PKR) and its prognostic significance in lymph node negative rectal cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 9, 2005, Pages 545-550

  Kwon, Hyuk Chan ^a   Moon, Chang Hoon ^a   Kim, Sung Hyun ^a   Choi, Hong Jo ^a   Lee, Hyung Sik ^a   Roh, Mee Sook ^a   Hwang, Tae Ho ^a   Kim, Jae Seok ^a   Kim, Hyo Jin ^a  

^a Dong A University   (South Korea)

Author keywords

Immunohistochemistry; PKR; Prognosis; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TJ4C4; OXALIPLATIN; PROTEIN KINASE R; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; MORTALITY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM CANCER; RECTUM RESECTION; RETROSPECTIVE STUDY; SCORING SYSTEM; STAINING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; EIF-2 KINASE; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RNA, DOUBLE-STRANDED; SURVIVAL RATE;

EID: 27644461968     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi146     Document Type: Article

References (17)

1. Shin HR, Won YJ, Jung KW, Park JG. 2001 Annual report of the Korea central cancer registry: Based data from 134 hospitals. Cancer Res Treat 2004;36:19-30.
2. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
3. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomized trials. Lancet 2001;358:1291-304.
4. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5-FU with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
5. Seong J, Chung EJ, Kim H, Kim GE, Kim NK, Sohn SK, et al. Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas. Int J Radiat Oncol Biol Phys 1999;45:1167-73.
6. Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 2004;22:1572-82.
7. Jagus R, Joshi B, Barber GN. PKR, apoptosis and cancer. Int J Biochem Cell Biol 1999;31:123-38.
8. Haines GK 3rd, Becker S, Ghadge G, Kies M, Pelzer H, Radosevich JA. Expression of the double-stranded RNA-dependent protein kinase (p68) in squamous cell carcinoma of the head and neck region. Arch Otolaryngol Head Neck Surg 1993;119:1142-7.
9. Singh C, Haines GK, Talamonti MS, Radosevich JA. Expression of p68 in human colon cancer. Tumour Biol 1995;16:281-9.
10. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 2004;22:1785-96.
11. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996-9.
12. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19:157-63.
13. WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-401.
14. Gil J, Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): Mechanism of action. Apoptosis 2000;5:107-14.
15. Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines GK 3rd, et al. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours. Eur J Cancer 1998;34:2046-52.
16. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 1995;14:6095-106.
17. Kim SH, Forman AP, Mathews MB, Gunnery S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 2000;19:3086-94.